Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies

Conditions

• Pancreatic Cancer
• Small Bowel Cancer
• Colorectal Cancer
• Melanoma
• Non Small Cell Lung Cancer
• Thyroid Cancer
• Bladder Cancer
• Head and Neck Cancer
• Gastric Cancer
• Esophageal Cancer
• Cholangiocarcinoma
• Ovarian Cancer
• Hepatocellular Carcinoma
• Glioblastoma
• MAPK Gene Mutation
• KRAS Activating Mutation
• BRAF Gene Mutation
• NRAS Gene Mutation
• HRAS Gene Mutation
• MEK Mutation
• ERK Mutation

Interventions

• DRUG: Ulixertinib (BVD-523)

Sponsor

xCures

Collaborators

• [object Object]